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Background/aims: The Baveno VI consensus recommendations propose the 
use of liver stiffness (LS) by transient elastography (TE) as a tool for suspected 
compensated advanced chronic liver disease (cACLD): a LS<10 KPa in the 
absence of other clinical signs rules out and a LS>15 KPa is highly suggestive of 
cACLD. We aimed to validate these criteria in an individual patient meta-
analysis. 
Methods: We included patients from eight centres (Bordeaux n=1335, Cluj 
n=1180, Palermo n=808, Angers n=518, Firenze n=334, Royal Free n=303, 
Athens n=154, Beaujon n=75) who had a liver biopsy and TE within 6 months. 
We only included patients with well-compensated liver disease and a diagnosis 
of chronic hepatitis B (CHB), chronic hepatitis C (CHC) or non-alcoholic fatty 
liver disease (NAFLD). METAVIR was used as the staging system for fibrosis and 
cACLD was defined as a fibrosis stage of ≥F3. The interquartile range/median 
ratio (IQR/M) was used for the assessment of TE reliability as previously 
published: "very reliable" (IQR/M ≤0.10), "reliable" (0.10< IQR/M ≤0.30, or 
IQR/M >0.30 with LS median <7.1 kPa), and "poorly reliable" (IQR/M >0.30 with 
LS median ≥7.1 kPa). 
Results: There were 4707 patients evaluated; in 247 (5.2%), TE was not 
technically possible and 267 (5.7%) had a poorly reliable measurement, 
therefore 4198 were considered for the analysis. Mean age was 49.8±12.7, BMI 
26.7±4.9 kg/m2, 52.8% were males and the majority had CHC (n=2609, 62%) 
followed by NAFLD (n=894, 21.2%) and CHB (n=695, 16.6%). Fibrosis 
distribution was: F0 433 (10.3%), F1 1320 (31.4%), F2 1227 (29.2%), F3 689 
(16.4%), F4 529 (12.6%). A LS<10 KPa had an 86.8% specificity for ruling out 
cACLD and a LS>15 KPa had a 96.8% sensitivity for ruling in cACLD. Use of the 
dual cut-off would result at 671 (16%) patients being classified as indeterminate 
and would require a further diagnostic test.  
Conclusions: Liver stiffness by TE at a cut-off of >15 has an excellent sensitivity 
for ruling in cACLD, while a cut-off of <10 has a moderate specificity for ruling 
out cACLD and should be interpreted in the clinical context of each individual 
case. 
 
